You are here

Cancer Res DOI:10.1158/0008-5472.CAN-21-0301

60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy.

Publication TypeJournal Article
Year of Publication2021
AuthorsCieri, N, Maurer, K, Wu, CJ
JournalCancer Res
Volume81
Issue17
Pages4373-4384
Date Published2021 Sep 01
ISSN1538-7445
Abstract

The year 2020 marked the 30th anniversary of the Nobel Prize in Medicine awarded to E. Donnall Thomas for the development of allogeneic hematopoietic stem cell transplantation (allo-HSCT) to treat hematologic malignancies and other blood disorders. Dr. Thomas, "father of bone marrow transplantation," first developed and reported this technique in 1957, and in the ensuing decades, this seminal study has impacted fundamental work in hematology and cancer research, including advances in hematopoiesis, stem cell biology, tumor immunology, and T-cell biology. As the first example of cancer immunotherapy, understanding the mechanisms of antitumor biology associated with allo-HSCT has given rise to many of the principles used today in the development and implementation of novel transformative immunotherapies. Here we review the historical basis underpinning the development of allo-HSCT as well as advances in knowledge obtained by defining mechanisms of allo-HSCT activity. We review how these principles have been translated to novel immunotherapies currently utilized in clinical practice and describe potential future applications for allo-HSCT in cancer research and development of novel therapeutic strategies.

DOI10.1158/0008-5472.CAN-21-0301
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/34108142?dopt=Abstract

Alternate JournalCancer Res
PubMed ID34108142
PubMed Central IDPMC8416782
Grant ListP01 CA229092 / CA / NCI NIH HHS / United States
T32 HL116324 / HL / NHLBI NIH HHS / United States